Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration  by Rosengart, Todd K. et al.
PERIOPERATIVE MANAGEMENTPlatelet activity measured by a rapid turnaround assay identifies
coronary artery bypass grafting patients at increased risk for bleeding
and transfusion complications after clopidogrel administrationTodd K. Rosengart, MD,a,b Jamie L. Romeiser, MPH,c Lauren J. White, BS,c Ashley Fratello, BA,c
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http://dxBackground: We sought to establish a metric for easily estimating bleeding and transfusion risks for cardiac
surgery patients after antiplatelet agent use.
Methods: Deidentified records of patients who underwent coronary artery bypass grafting (CABG) at our
institution (January 2010-June 2011) were searched for patients without identified risk factors for excessive
bleeding who underwent documented P2Y12 testing after clopidogrel administration (n ¼ 276). Clinical out-
comes were analyzed according to whether preoperative platelet function was higher (platelet reactivity units
[PRUs], 237) or lower (PRU,<237) and according to preoperative PRU cutoffs: high (>290, or no clopidog-
rel), intermediate (200-290), or low (<200).
Results: Eighty-five patients (57%) received allogeneic blood products at 24 hours or less postoperatively: 33
(22%) received fresh frozen plasma, and 57 (38%) received platelets. The median 12-hour chest tube output
(CTO) was 350 mL (interquartile range, 260-490 mL); CTO was ‘‘high’’ (>437 mL) in 62 (42%) of the
clopidogrel-treated patients. Lower-PRU patients were more likely to receive coagulation factors (odds ratio
[OR], 2.82; P ¼ .0004) and to have high CTO or coagulation factor transfusion (OR, 2.35; P ¼ .02) than
higher-PRU patients. Likewise, intermediate- and low-PRU patients had incrementally greater incidences of
high CTO (OR, 1.72; P¼ .002) and coagulation factor transfusion (OR, 2.08; P<.0001) than high-PRU/no clo-
pidogrel patients. High CTO or coagulation factor transfusion was more frequent in intermediate-PRU
(OR, 2.67; P ¼ .02) and low-PRU (OR, 5.08; P ¼ .0002) patients than in high-PRU/no clopidogrel patients.
Conclusions:Among clopidogrel-treatedCABGpatients, preoperative platelet function testing can identify those
at increased risk for postoperative bleeding and transfusion. (J Thorac Cardiovasc Surg 2013;146:1259-66)Supplemental material is available online.
Many patients who undergo open heart surgery are
receiving long-term antiplatelet treatment at the time of
the procedure because of recent percutaneous coronary
intervention (PCI), for acute coronary syndromes, or for
other reasons.1 More specifically, nearly 21% of patients
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Martery bypass grafting (CABG) surgery, and nearly 13%
of CABG patients present for surgery while receiving clo-
pidogrel or another adenosine diphosphate inhibitor.2,3
Patients who undergo CABG while receiving such
antiplatelet therapy have been reported to be at an
increased risk of bleeding, transfusion complications,
reoperation for bleeding, and mortality.4-8 However,
discontinuing antiplatelet therapy may increase patients’
risk of ischemic events, including stent thrombosis.9,10 It
is important to balance these risks when deciding
whether clopidogrel should be discontinued for a given
patient.1,11-14
The ‘‘2012 ACCF/AHA focused update of the guideline
for the management of patients with unstable angina/
non-ST-elevation myocardial infarction’’ recommends
withdrawing clopidogrel at least 5 days before CABG.15
However, there is marked variability in patients’ responses
to clopidogrel therapy because of variations in patient geno-
type, as well as other factors.16-18 This considerable
heterogeneity potentially makes it difficult to safely use
such an arbitrary interval for discontinuing clopidogrel
treatment before CABG without incurring excessive
thrombotic or bleeding risks with premature versus
excessively delayed discontinuation, respectively.diovascular Surgery c Volume 146, Number 5 1259
Abbreviations and Acronyms
ACCF ¼ American College of Cardiology
Foundation
AHA ¼ American Heart Association
BSA ¼ body surface area
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CTO ¼ chest tube output
IQR ¼ interquartile range
OR ¼ odds ratio
PCI ¼ percutaneous coronary intervention
PRU ¼ platelet reactivity units
QA ¼ quality assurance
SBU ¼ Stony Brook University
SQDUG ¼ Surgical Quality Data Users Group
SQIP ¼ Surgical Quality Improvement Program
STS ¼ Society of Thoracic Surgeons
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MTo implement these American College of Cardiology
Foundation (ACCF)/American Heart Association (AHA)
guidelines optimally, cardiac surgeons need to understand
how their patients previously prescribed clopidogrel have
responded to it. As part of the preoperative assessment of
these patients, platelet functioning tests may be useful in
identifying patients whose individual response to clopidog-
rel treatment puts them at highest risk of bleeding or throm-
botic complications. Therefore, the purpose of this study
was to identify preoperative ‘‘high-risk’’ cardiac surgery
patients from preoperative platelet function testing.
METHODS
Design
As part of the Surgical Quality Improvement Program (SQIP) of the
Stony Brook University (SBU) School of Medicine’s Division of Cardio-
thoracic Surgery in theDepartment of Surgery, an expanded patient registry
was designed and authorized by the SBU School of Medicine’s Division of
Medical and Regulatory Affairs. Under this program, SQIP routinely re-
ported safety and outcomes data for all cardiac surgical patients to the Di-
vision of Cardiothoracic Surgery, Department of Surgery, and institutional
quality assurance (QA) committees. The SQIP database comprised data
from other QA program databases, including the New York State Cardiac
Surgery Reporting System and the Society of Thoracic Surgeons (STS)
National Adult Cardiac Surgery Database, as well as our cardiac surgery
patient records. Moreover, for specific SBU QA projects, supplemental
data were extracted from the medical records of surgical patients.
A Surgical Quality Data Users Group (SQDUG) secondarily reviewed
and provided approval, as appropriate, of analyses of data extracts from pa-
tient records deidentified by the SQIP group, under the SQDUG protocol
approved by the SBU School Institutional Review Board (Committee on
Research in Human Subjects 170753-5). Under these protocols, this study
was approved as a retrospective cohort study using deidentified records that
had previously been gathered for QA reporting purposes.
Study Population
Deidentified records were extracted for all patients who underwent a
‘‘CABG-only’’ procedure at our institution from January 2010 to June1260 The Journal of Thoracic and Cardiovascular Sur2011 (n ¼ 366). These patients underwent coronary bypass procedures
either off-pump orwith cardiopulmonary bypass andmild tomoderate hypo-
thermia according to our clinical standards, including the use of cell salvage.
For this SQDUG-approved analysis, records were excluded for patients with
an excessive risk of bleeding or transfusion, as established by STS guide-
lines,14 including evidence of liver failure, dialysis, or renal dysfunction
(creatinine  1.5 mg/dL) (n ¼ 38). Patients were also excluded for nonas-
pirin, nonclopidogrelglycoprotein IIb/IIIa inhibitor use (n¼8)or clopidogrel
usewithout P2Y12 testing (n¼ 18), or if their recordwas incomplete (n¼ 26).
Platelet Functional Monitoring
Preoperative platelet function was assayed using fresh blood samples
drawn within 24 hours of surgery by measuring P2Y12 receptor blockade
with the VerifyNow system (Accumetrics, San Diego, Calif). Technical de-
tails have been described elsewhere.19 For this study, historically reported
platelet inhibition levels were converted into the inversely correlated
platelet reactivity unit (PRU) scale more recently proposed by the vendor
(Appendix 1, available online). A platelet inhibition level of 20% or
less, which was previously considered a negligible or ‘‘safe’’ level of
platelet inhibition for patients undergoing coronary bypass surgery,20
was accordingly translated into a PRU threshold of 237 or more (with a
receiver-operator characteristic area under the curve of 0.93).
CABG-Related Bleeding Outcomes
Chest tube output (within the first 12 hours postoperatively), intraoper-
ative and postoperative transfusions (within the first 24 hours), bleeding-
related complications (eg, reoperation for bleeding), 30-day operative
mortality, 30-day readmission, and prolonged postoperative length of
stay (greater than the upper 95% confidence limit for the ‘‘no clopidogrel’’
control group) served as the main outcomes for this study. Because patients
with no preoperative use of clopidogrel may be regarded as having a
‘‘normal’’ 12-hour chest tube output, this subset’s upper limit threshold
(95% confidence interval [CI]) was used as the cutoff value to dichotomize
a chest tube output that was normal versus significantly higher than normal.
In addition to the total units of allogeneic blood product transfused, trans-
fusions were also coded dichotomously with regard to whether any amount
of a given product—allogeneic red blood cells, platelets, or fresh frozen
plasma—had been transfused intraoperatively or within 24 hours postoper-
atively. Finally, a composite outcome indicative of surgery-related bleeding
events was defined as ‘‘high’’ chest tube output or coagulation product
(platelet or fresh frozen plasma) transfusion.
Statistical Analysis: Primary Hypothesis Testing
To test our primary study hypothesis, we divided the patients into 2
groups according to their preoperative platelet function: higher PRU
(237; ie, the literature-based threshold for bleeding due to platelet
dysfunction, equivalent to 0%-20% platelet inhibition) and lower PRU
(<237; ie, the literature-based equivalent to platelet inhibition>20%).20
Outcomes between these groups were compared by using c2 and Fisher
exact tests. Differences in demographics and preoperative medication use
were adjusted for by multivariate logistic regression to determine whether
the higher- and lower-PRU groups differed with regard to CABG bleeding-
related outcomes. A 95% CI was used. All calculations were performed
with SAS, version 9.2, software (SAS Institute, Inc, Cary, NC).
Exploratory Analyses
For supplemental analyses, the PRU predictor variable was recatego-
rized through histogram plotting (Figure 1). A threshold analysis was per-
formed to identify PRU cutoffs to optimize differences between subgroup
outcomes using the estimation approach described by Tobin.21 This anal-
ysis separated patients into 3 groups on the basis of platelet function:
high-PRU (>290), intermediate-PRU (200-290), and low-PRU (<200).
These 3 groups’ outcomes were compared by using c2, Fisher exact, andgery c November 2013
FIGURE 1. Platelet reactivity units (PRUs) as assayed by measuring P2Y12 receptor blockade within 24 hours of surgery for patients who received
clopidogrel before coronary bypass surgery (n ¼ 149). This analysis separated the patients into 3 groups on the basis of platelet function: high PRU
(>290), intermediate PRU (200-290), and low PRU (<200).
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MWilcoxon rank-sum tests. As appropriate, other patient risk factors were
included as covariates in a multivariate logistic regression.
RESULTS
Patient Characteristics
After excluding patients with risk factors for bleeding or
transfusion (as previously noted), our final CABG cohort
comprised 149 patients (54% of total) who had received
preoperative clopidogrel and 127 patients (46% of total)
who had not received clopidogrel preoperatively. The 149
patients who underwent CABG after clopidogrel adminis-
tration were predominantly male (81%), white (91%),
and non-Hispanic (95%), with a median age of 65 years (in-
terquartile range [IQR], 58-73 years) and a mean body sur-
face area (BSA) of 2.0 (range, 1.9-2.2). Operation was
defined as urgent in 145 (97%) of cases (Table 1).
Regarding preoperative risk factors for bleeding or trans-
fusion, 105 (70%) of the patients had received aspirin, 13
(9%) had a history of peripheral vascular disease, and
104 (70%) had abnormally low hematocrit (<42%). Off-
pump surgery was performed in 59 cases (40%). The
average number of distal bypasses was 3.4 (95% CI, 3.2-
3.5). Crossclamp and cardiopulmonary bypass times were
57 (95% CI, 53-60) and 90 (95% CI, 85-96) minutes,
respectively. Epsilon amino-caproic acid was administered
in 270 (98%) of cases, whereas tranexamic acid was admin-
istered in no cases. No patient had evidence of sepsis/shock
or a history of coagulopathy.
Clinical Outcomes
Overall, the 30-day operative mortality rate for our study
cohort was 3% (Table 1). Three patients (2%) requiredThe Journal of Thoracic and Carreoperation for bleeding, and 21 patients (14%) were read-
mitted within 30 days of primary discharge. The median
postoperative length of stay was 5 days (IQR, 4-6 days).
The number of patients transfused with any allogeneic
blood products either intraoperatively or within 24 hours
postoperatively was 85 (57%): 33 (22%) were transfused
intraoperatively only, 19 (13%) were transfused postopera-
tively only, and 33 (22%) were transfused during both time
intervals (Table 2). Of these patients, 63 (43%) received an
allogeneic red blood cell transfusion, 33 (22%) received a
fresh frozen plasma transfusion, and 57 (38%) received a
platelet transfusion.
The median 12-hour chest tube output was 350 mL
(IQR, 260-490 mL). Based on the mean and 95% CI for
12-hour chest tube output calculated for the no clopidogrel
control group (mean, 398 mL; 95% CI, 359-437 mL), the
dichotomous end point for high 12-hour chest tube output
(defined as 12-hour chest tube output>437 mL) occurred
in 62 patients (42%) in the clopidogrel-treated group.Platelet Reactivity Groups
Eighty-five (57%) of the clopidogrel-treated patients
were categorized as having higher platelet reactivity (PRU
237), and the remaining 64 (43%) were classified as hav-
ing lower platelet reactivity (PRU 0-236). There were no
differences (P> .1) between these 2 groups in nearly all
bleeding/transfusion risk factors (including age, sex, BSA,
urgent/emergent surgery, on/off-pump procedures, and pre-
operative use of aspirin), except that higher-PRU patients
were more likely to have an abnormal hematocrit when
they entered the operating room (P ¼ .04, Table 3).diovascular Surgery c Volume 146, Number 5 1261
TABLE 1. Descriptive characteristics of the clopidogrel-treated
CABG cohort
Descriptive
characteristics All (N ¼ 149)
Higher PRU
(PRU, 237;
n ¼ 85)
Lower PRU
(PRU, 0-236;
n ¼ 64)
Sex
Female 29 (19) 19 (22) 10 (16)
Male 120 (81) 66 (78) 54 (84)
Race
White 135 (91) 74 (87) 61 (95)
Black/African
American
3 (2) 3 (4) 0 (0)
Other 11 (7) 8 (9) 3 (45)
Ethnicity
Hispanic 7 (5) 3 (4) 4 (6)
Non-Hispanic 141 (95) 82 (96) 59 (92)
Priority
Elective 1 (1) 1 (1) 0 (0)
Emergent 3 (2) 3 (4) 0 (0)
Urgent 145 (97) 81 (95) 64 (100)
Age, y 65 (58-73) 66 (58-73) 63.5 (57-73)
Body surface area, m2 2 (1.9-2.2) 2 (1.9-2.2) 2 (1.9-2.2)
Diabetes mellitus 59 (40) 38 (45) 21 (33)
OR entry/exit time, min 328 (293-376) 333 (301-370) 326 (282-378)
Reoperation for bleeding 3 (2) 1 (1) 2 (3)
PLOS high 36 (24) 22 (26) 14 (22)
Readmission (30 d) 21 (14) 11 (13) 10 (16)
Mortality (30 d) 4 (3) 1 (1) 3 (5)
Data are presented as number (%) or median (interquartile range). CABG, Coronary
artery bypass grafting; PRU, platelet reactivity unit; OR, operating room; PLOS, pro-
longed postoperative length of stay (>95% confidence interval upper limit threshold
for the no clopidogrel use group:>6.17 d).
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The incidence of transfusion of coagulation factors
(ie, platelets or fresh frozen plasma) differed significantly
between the PRU groups, as did the incidence of high chest
tube output (Table 3). Univariate analysis showed that,
compared with the higher-PRU group, the lower-PRU group
was more likely to have a high chest tube output at 12 hours
(odds ratio [OR], 1.99; 95% CI, 1.02-3.88; P¼ .04; c-index,
0.584) and to have a coagulation factor transfusionTABLE 2. Perioperative transfusions for PRU groups
Transfusion characteristics
All (N ¼ 149) Highe
No. (%) Median (IQR)* No. (%
Any transfusion 85 (57) 3 (2-6) 48 (5
Intraoperative only 33 (22) 3 (2-3) 21 (2
Postoperative (within 24 h) only 19 (13) 2 (1-4) 10 (1
Both intraoperative and
postoperative
33 (22) 5 (4-7) 17 (2
Red blood cell transfusion 63 (42) 2 (1-3) 39 (4
Platelet transfusion 57 (38) 2 (1-3) 24 (2
Fresh frozen plasma transfusion 33 (22) 2 (2-3) 16 (1
PRU, Platelet reactivity unit; IQR, interquartile range. *Median (IQR) is reported for individ
the calculation.
1262 The Journal of Thoracic and Cardiovascular Sur(OR, 2.33; 95% CI, 1.2-4.54; P ¼ .01; c-index, 0.603).
The incidence of the composite outcome of high chest
tube output or coagulation factor transfusion (OR, 2.46;
95% CI, 1.22-4.95; P ¼ .012) showed the highest predict-
ability as a function of PRU group (c-index, 0.606).
Multivariate models were adjusted for the difference be-
tween groups in the prevalence of abnormal preoperative
hematocrit—the only bleeding/transfusion risk factor that
varied between groups—and the c-indices from all multi-
variate models indicated a better predictive fit than their
univariate counterparts (Table 4). By multivariate analysis,
the lower-PRU group was again more likely to have a coag-
ulation factor transfusion (OR, 2.82; 95% CI, 1.39-5.73;
P¼ .0004; c-index, 0.642) and more likely to have the com-
bination outcome of either high chest tube output or coagu-
lation factor transfusion (OR, 2.35; 95% CI, 1.15-4.8;
P ¼ .02; c-index, 0.635) than the higher-PRU group.
However, multivariate analysis showed that chest tube
output alone was not significantly different between the
higher- and lower-PRU groups (P ¼ .09).
Exploratory Analysis
To explore the possibility of generating bleeding/transfu-
sion outcomes data that more closely reflect the population
of patients presenting for open heart surgery after clopidog-
rel treatment, cutoff points in the distribution of the PRU
assay results (Figure 1) were used to define the 3 PRU com-
parison groups: high (PRU,>290; n ¼ 48), intermediate
(PRU, 200-290; n ¼ 61), and low (PRU,<200; n ¼ 40).
Furthermore, because patients who had not received clopi-
dogrel before CABG (the no-clopidogrel control group;
n ¼ 127) did not differ significantly from the high-PRU
group in key risk factors and outcomes, these 2 groups
were combined in this supplemental analysis (n ¼ 175).
There were no differences among the low-PRU,
intermediate-PRU, and high-PRU/no-clopidogrel groups
in nearly all bleeding and transfusion risk factors (including
age, sex, BSA, urgent/emergent surgery, on/off-pump
procedures, and preoperative hematocrit), except for
preoperative use of aspirin, which was greater in ther PRU (PRU, 237; n ¼ 85) Lower PRU (PRU, 0-236; n ¼ 64)
) Median (IQR)* No. (%) Median (IQR)*
7) 3 (2-5) 37 (58) 4 (2-6)
5) 2 (2-3) 12 (19) 3 (2-6.5)
2) 2 (1-3) 9 (14) 1 (1-4)
0) 6 (3-7) 16 (25) 5 (4-7.5)
6) 2 (1-3) 24 (38) 2 (1.5-3)
8) 2 (1-3) 33 (52) 2 (1-2)
9) 2 (2-2.5) 17 (27) 2 (2-3)
uals with a positive indication for that trait; thosewithout the trait were not included in
gery c November 2013
TABLE 3. Analysis of risk factors and bleeding/transfusion outcomes for PRU groups
Patient characteristics All (N ¼ 149)
Higher PRU
(PRU, 237; n ¼ 85)
Lower PRU
(PRU, 0-236; n ¼ 64) c2/Fisher P value
Demographics
Female sex 29 (19) 19 (22) 10 (16) .305
Preoperative risk factors
Aspirin 105 (70) 63 (74) 42 (66) .324
Peripheral vascular disease 13 (9) 5 (6) 8 (13) .095
Abnormal (low) hematocrit* 106 (71) 66 (78) 40 (63) .043
Operative risk factors
Off-pump procedure 59 (40) 30 (35) 29 (45) .216
Composite clinical outcomey 57 (38) 33 (39) 24 (38) .869
Bleeding/transfusion outcomes
Red blood cell transfusion 63 (42) 39 (46) 24 (38) .305
Coagulation factor transfusion 64 (43) 29 (34) 35 (55) .012
High chest tube outputz 62 (42) 29 (34) 33 (52) .033
Bleeding/transfusion composite outcomex 92 (62) 45 (53) 47 (73) .011
PRU, Platelet reactivity unit. *Abnormal hematocrit: male,<42%; female,<37%. yComposite clinical outcome: 30-d postoperative mortality, reoperation for bleeding, pro-
longed postoperative length of stay (>95% confidence interval upper limit threshold for the no clopidogrel use group,>6.17 d; readmission within 30 d of primary hospital
discharge). zHigh chest tube output: 12-h output, greater than 437 mL. xHigh chest tube output or coagulation factor transfusion.
Rosengart et al Perioperative Managementintermediate-PRU group than in the other 2 groups (Table
5). Therewas likewise no difference between groups in clin-
ical outcomes, including intensive care unit stay or time on
ventilator, or the composite outcome of 30-day postopera-
tive mortality, reoperation for bleeding, postoperative
length of stay greater than 1 SD from mean, and readmis-
sion within 30 days of primary hospital discharge (Table 5).
When evaluated successively, univariate analysis showed
that the odds of having high chest tube output or coagulation
factor transfusion increased significantly as an incremental
function of this supplemental PRU grouping (OR, 2.26;
P<.0001; Table 4).
Multivariate models adjusted for preoperative use of
aspirin all indicated a better predictive fit than theirTABLE 4. Univariate analysis of bleeding/transfusion outcomes as a
function of exploratory PRU group
Bleeding outcomes Odds ratio 95% CI P value c-index
High chest tube output* 1.71 1.22-2.38 .002 0.598
High PRU/no clopidogrel 1.0
Intermediate PRU 1.83 1.0-3.33 .049
Low PRU 2.81 1.40-5.67 .004
Coagulation factor
transfusion
2.03 1.45-2.85 <.0001 0.623
High PRU/no clopidogrel 1.0
Intermediate PRU 1.69 0.92-3.09 .09
Low PRU 4.51 2.18-9.34 <.0001
High chest tube output or any
coagulation factor
transfusion*
2.26 1.56-3.26 <.0001 0.633
High PRU/no clopidogrel 1.0
Intermediate PRU 2.26 1.24-4.12 .008
Low PRU 5.09 2.23-11.68 .0001
PRU, Platelet reactivity unit; CI, confidence interval. *High chest tube output: 12-h
output, greater than 437 mL.
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Munivariate counterparts (Table E1); all outcomes were
significantly different across the supplemental PRU group-
ings. By this analysis, the ORs compared with the
high-PRU/no-clopidogrel (ie, reference) group were each
incrementally greater in the intermediate- and low-PRU
groups for high chest tube output (OR, 1.72; 95% CI,
1.23-2.42; P ¼ .002; c-index, 0.625) and for coagulation
factor transfusion (OR, 2.08; 95% CI, 1.47-2.94;
P< .0001; c-index, 0.65). The ORs for high chest tube
output were 2.08 (95% CI, 1.12-3.86; P ¼ .02) and 2.73
(95% CI, 1.34-5.57; P ¼ .006) for the intermediate- and
low-PRU groups, respectively, versus the reference group,
and the ORs for coagulation factor transfusion were 1.95
(95% CI, 1.04-3.63; P ¼ .037) and 4.46 (95% CI, 2.13-
9.33; P<.0001), respectively. The OR for high chest tube
output or coagulation factor transfusion as a composite in-
dex was also significantly higher in the intermediate-PRU
(OR, 2.67; P ¼ .02) and low-PRU (OR, 5.08; P ¼ .0002)
groups than in the reference group (Table E1).
DISCUSSION
This study showed that the risks of bleeding and transfu-
sion in patients who undergo CABG after clopidogrel
administration can be predicted by a point-of-care platelet
reactivity assay. These preliminary findings suggest specific
platelet activity thresholds (represented by cut points in
PRU, as measured by this assay) that could be used to pre-
dict a patient’s risk of bleeding and transfusion complica-
tions. Thus, clinicians may be able to better manage the
timing of CABG after clopidogrel cessation by using such
point-of-care testing rather than adhering to arbitrary time
intervals, such as those advocated by the ACCF/AHA
guidelines. More specifically, our data indicate that using
these platelet reactivity guidelines to determine the intervaldiovascular Surgery c Volume 146, Number 5 1263
TABLE 5. Risk factors and outcomes for exploratory PRU groups
Patient characteristics
High
(PRU,>290; n ¼ 175)
Intermediate
(PRU, 200-290; n ¼ 61)
Low
(PRU,<200; n ¼ 40) c2/Fisher P value
Demographics
Female sex 43 (25) 10 (16) 5 (14) .1447
Preoperative risk factors
Aspirin 104 (59) 49 (80) 22 (55) .009
Peripheral vascular disease 25 (14) 3 (5) 7 (18) .092
Abnormal (low) hematocrit
in the OR*
124 (71) 42 (69) 24 (60) .409
Operative risk factors
Off-pump procedure 57 (33) 25 (41) 19 (48) .151
Composite clinical outcomey 71 (41) 21 (34) 16 (40) .694
Bleeding/transfusion
outcomes
Red blood cell transfusion 67 (38) 22 (36) 17 (43) .808
Coagulation factor
transfusion
51 (29) 25 (41) 26 (65) <.0001
High chest tube outputz 53 (30) 27 (44) 22 (55) .0057
Bleeding/transfusion
composite outcomex
77 (44) 39 (64) 32 (80) <.0001
PRU, Platelet reactivity unit; OR, operating room. *Abnormal hematocrit: male,<42%; female,<37%. yComposite clinical outcome: 30-d postoperative mortality, reoperation
for bleeding, prolonged postoperative length of stay (>95% confidence interval upper limit threshold for the no clopidogrel use group:>6.17 d), and readmission within 30 d of
primary hospital discharge. zHigh chest tube output: 12-h output, greater than 437 mL. xHigh chest tube output or coagulation factor transfusion.
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vent excessive thrombosis risk while also minimizing
bleeding risk.
The increased risk of bleeding during and after CABG
performed on patients who are receiving antiplatelet ther-
apy, specifically clopidogrel, has been well estab-
lished.4,5,9,10,22,23 More recently, the ability of clopidogrel
to inhibit platelet activity by its blockade of the P2Y12
platelet receptor has varied as a function of the expression
of the relevant CYP2C19*17 and CYP2C19*2 and *3
alleles governing the expression and activity of this
receptor.24 As a result of this heterogeneity in genetic
expression, responses to clopidogrel treatment have varied
widely across populations, and levels of platelet inhibition
cannot, therefore, be predicted on the basis of clopidogrel
dose or the length of the dosing-cessation interval.6,11,16,18
In this regard, the marked variability in patient response
to clopidogrel therapy makes it challenging to identify
those patients who are most at risk of excessive bleeding
complications on the basis of their history of antiplatelet
drug use. Point-of-care platelet functional testing before
surgery, therefore, provides an objective measurement of
platelet inhibition and a mechanism to predict antiplatelet
agent–mediated bleeding risk.
The role of preoperative platelet function testing in pre-
dicting bleeding risk has been reviewed by Gurbel and col-
leagues.25 They noted that Chen and colleagues22 were the
first to show an association between platelet aggregation, as
measured by light transmittance aggregometry, and CABG-
related bleeding in patients who underwent on-pump1264 The Journal of Thoracic and Cardiovascular SurCABG operations. In their report, of those patients with se-
vere platelet dysfunction of less than 40% light transmit-
tance, 92% received multiple transfusions. Kwak and
colleagues26 likewise found that patients who underwent
off-pump CABG with platelet inhibition levels greater
than 76% had increased chest tube output and higher trans-
fusion requirements.
Compared with many of the assays used in these previous
studies, the P2Y12 assay used in the current study is rapid
and readily deployed, with report times as brief as only a
few hours, even as point-of-care testing. In addition, this
assay is precise enough to allow clinicians to set clear
PRU thresholds for predicting bleeding risk, as has been
previously suggested.27 With this method, a 20% threshold
for platelet inhibition has been used to guide the clinical
management of bleeding occurrences,20 and another study
identified a PRU of 189 as the threshold for increased
bleeding risk in patients who undergo PCI.27
Unlike many prior CABG studies, our study was an
institution-specific evaluation of a time-independent
threshold for distinguishing between high- and normal-risk
clopidogrel-treated patients. Furthermore, our exploratory
analysis identified thresholds for high, intermediate, and
nonsignificant risk compared with non–clopidogrel-treated
patients, making it possible to balance bleeding risk against
ischemic risk and urgency of operation. Using these PRU-
level thresholds enabled us to identify a high-risk group of
patients with an 80% risk of high chest tube output or coag-
ulation factor transfusion. We chose this composite end
point because it incorporates 2 outcomes whose incidencegery c November 2013
Rosengart et al Perioperative Managementin clopidogrel recipients is inversely related: ‘‘prophylac-
tic’’ administration of coagulation factors and the incidence
of high chest tube output. In consideration of this dual
outcome, further delay of surgical intervention would
appear to be clearly indicated in such a subpopulation.Study Limitations
The current study has several limitations, including the
potential for confounding that is inherent to this study’s
retrospective design, as well as the fact that transfusion trig-
gers were not used in the management of the patients. Also,
the possibility for preclinical bias exists; however, the prev-
alences of most known bleeding risk factors were similar
among the study groups, and the study’s outcomes were sta-
tistically significant even after multivariate adjustments for
other bleeding-related risk factors. In addition, although
precautions against bleeding and transfusion, including pa-
tient rewarming after bypass and the use of cell salvage,
were taken as a matter of standard clinical practice at our
institution, no standard algorithm was followed for manag-
ing bleeding in these patients. Despite these limitations, our
transfusion rate of approximately 50% overall is similar to
the 56% transfusion rate for CABG reported in the STS
database,2 suggesting that the blood conservation practices
used in this study were consistent with national norms.P
MCONCLUSIONS
Our findings support the use of separate cut points for
platelet activity–assay results to identify CABG patients
who are at high risk of bleeding and transfusion, specifically
among patients who were previously receiving the anti-
platelet agent clopidogrel. Additional studies are warranted
to test whether these preliminary cut points could be used
more broadly to support clinical decision making, such as
choosing the best time interval between clopidogrel discon-
tinuation and CABG to minimize bleeding and transfusion
risk. Moreover, it will be important to determine whether
using platelet activity assay thresholds yields better out-
comes overall (with regard to bleeding, transfusion, major
adverse cardiac events, and length of stay) than using cur-
rent standards based on arbitrary time delay intervals.
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Discussion
Dr SongWan (Sha Tin, Hong Kong). Thank you, Dr Rosengart,
for this timely and important study and congratulations for this
elegant presentation.
I have just a few short questions for you. The first question re-
lates to the patient factor. Did all patients continue their aspirin
before operation and through the operating day? If yes, your obser-
vation may not make 100% perfect sense unless you demonstrate
that all the patients actually have the similar responsiveness to
aspirin among all 3 groups.
And in the meantime, the recently published PARADOX study
suggests a nonsmoker had reduced responsiveness to clopidogrel
than smokers. So I just wondered, do you have the data about
smoking status in all these patients, particularly the high function
and the low function groups? Maybe I’d let you answer the first
question.
Dr Rosengart. We did continue aspirin up to the time of use,
which is part of nearly all guidelines in this regard. There is now
apparent consensus that aspirin administration up to the time of1266 The Journal of Thoracic and Cardiovascular Sursurgery does not increase bleeding risks, but withdrawal in terms
of ACS syndromes does increase the risk of stent thrombosis, so
we continued ASA. We did correct for differences in ASA use
amongst groups in our final analysis, however.
There are, as you point out, a number of causes of the variability
of clopidogrel response, one being smoking; the most significant
cause was genetic heterogeneity in terms of liver metabolism of
the clopidogrel prodrug. This variability is, of course, accounted
for in our analysis using PRU as our input variable.
Dr Wan. And the second question relates to the preoperative
PRU measurement. Were those anesthetists and ICU staff actually
aware of the result? If yes, do you confirm actually the decision for
FFP and platelet transfusion was not biased by that result?
Dr Rosengart. Yes, that’s an important question. This was
retrospective, and in many cases, the surgeon, hopefully in all
cases, the surgeon was aware of the PRU response. In our analysis,
we consequently tried to capture a potential tradeoff between
bleeding and platelet transfusion as a composite adverse outcome
index—essentially, you pick your poison. Either you transfuse
platelets to minimize the bleeding, or try to avoid the platelet trans-
fusion, in which case you have a high chest tube output. This was
the rationale for our looking at a chest tube output, platelet trans-
fusion, in an either/or analysis. In fact, our findings support this as
the outcome of operating on low PRU patients—they are either
transfused or bleed, or in some cases both. What we found is
that you are either giving prophylactic platelet transfusion, which
in many cases was our practice, or looking at what the transfusion
and bleeding rates were and then correcting post hoc.
DrWan.My last question relates to the treatment. Some studies
suggested that tranexamic acid use could actually efficiently
reduce the bleeding in clopidogreltreated patients. So did any pa-
tients in your study receive tranexamic acid? If yes, what about the
duration intraoperatively and how many hours postoperatively?
Dr Rosengart. Nearly all (98%) of our patients received
Amicar. We do not use tranexamic acid.
Dr Wan. Thank you. And I thank the Association for the
privilege of discussing this paper. Thank you.gery c November 2013
TABLE E1. Adjusted logistic regression analysis of outcomes as a
function of exploratory PRU group*
Bleeding outcomes Odds ratio 95% CI P value c-index
High chest tube outputy 1.72 1.23-2.42 .002 0.625
High PRU/no clopidogrel 1.0
Intermediate PRU 2.08 1.12-3.86 .02
Low PRU 2.73 1.34-5.57 .006
Coagulation factor
transfusion
2.08 1.47-2.94 <.0001 0.65
High PRU/no clopidogrel 1.0
Intermediate PRU 1.95 1.04-3.63 .037
Low PRU 4.46 2.13-9.33 <.0001
High chest tube output or any
coagulation factor
transfusiony
2.36 1.61-3.47 <.0001 0.666
High PRU/no clopidogrel 1.0
Intermediate PRU 2.67 1.43-4.97 .02
Low PRU 5.08 2.19-11.77 .0002
PRU, Platelet reactivity unit; CI, confidence interval. *Model adjusted for preopera-
tive use of aspirin. yHigh chest tube output: 12-h output, greater than 437 mL.
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